Post Bariatric Hypoglycemia Clinical Trial
Official title:
A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia
NCT number | NCT02771574 |
Other study ID # | 36673 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | May 2016 |
Est. completion date | June 2017 |
Verified date | October 2020 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare disease with unmet clinical need.
Status | Completed |
Enrollment | 19 |
Est. completion date | June 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Post-bariatric surgery more than 6 months prior to signing the informed consent - Reported history of Whipple's triad: the occurrence of hypoglycemic symptoms associated with a capillary blood glucose of =55 mg/dL, and resolution with glucose or carbohydrate administration. - Symptomatic hypoglycemia during the baseline/screening oral glucose tolerance test (OGTT), as defined by the presence of plasma glucose =55 mg/dL with concomitant autonomic and/or neuroglycopenic symptoms. Exclusion Criteria: - Patients currently using sulfonylureas or other medications that may interfere with glucose metabolism within 5 half-lives of drug. - Participation in any clinical investigation within 4 weeks prior to dosing - History of or current insulinoma - Active infection or significant acute illness within 2 weeks prior to dosing - Female patients who are pregnant or lactating - Women of childbearing potential and not utilizing effective contraceptive methods - Inadequate end organ function |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Tracey McLaughlin | Eiger BioPharmaceuticals |
United States,
Tan M, Lamendola C, Luong R, McLaughlin T, Craig C. Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia. Diabetes Obes Metab. 2020 Aug;22(8):1406-1416. doi: 10.1111/ — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Nadir Glucose | Nadir glucose at baseline and at Day 3 of treatment during oral glucose tolerance test (OGTT). | Day 3 (time zero then every 30 minutes until 180 minutes or gylcemic rescue was required) | |
Secondary | Change in Composite Symptom Score as a Measure of Treatment Effect | Symptoms of hypoglycemia were assessed using the Edinburgh Hypoglycemia Symptom Scale that measures the intensity of 13 commonly experienced hypoglycemic symptoms, each severity graded on a 6-point Likert scale (0 = not present, 5 = severe). Scores are summed for a composite score ranging from 0 to 65, with higher scores corresponding to more severe hypoglycemia symptoms. | Baseline, Day 3 | |
Secondary | Pharmacokinetics of Subcutaneous Avexitide: Plasma Concentration Prior to Dosing (Co) | Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing. | Day 3 (Predose) | |
Secondary | Pharmacokinetics of Subcutaneous Avexitide: Maximum Plasma Concentration (Cmax) | Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing. | Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose) | |
Secondary | Pharmacokinetics of Subcutaneous Avexitide: Time of Maximum Plasma Concentration (Tmax) | Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing. | Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose) | |
Secondary | Pharmacokinetics of Subcutaneous Avexitide: Area Under the Plasma Concentration Versus Time Curve (AUC) | Pharmacokinetics of subcutaneous avexitide were assessed on Day 3 of twice daily dosing. | Day 3 (Predose, and 60, 120, 150, 180, 210, 240, 270, 300, 330, 450, 720 minutes post-dose) |